To further expand and increase its internal capability in developing new API, Olon announces the investment in a new spray dryer in its R&D centre based in Rodano (Milan, Italy).
The new equipment will be complementary to the freeze dryers, with which the R&D centre is already equipped. This is a step forward fitting into the strategic direction that the company is pursuing to create an internal “centre of excellence for finishing API.”
The centre of excellence, along with this new equipment, implies a continuous improvement of the skills applied to the characterization of the solid using different analytical technology already available in Olon, along its development. Olon can offer to the customer a wider and customized set of the API fully physically characterized meeting the customer demand for and optimal, efficient, and reproducible API formulation to guarantee the target bioavailability of the product.
The expertise, according to the company R&D model, will be applicable to all the other R&D Olon centres at the global level and to all the different therapeutic areas covered by Olon portfolio.
The investment fits into the vision of representing a Partner for pharma companies, enhancing competitiveness by catching the best time to market, and supporting early launches of generics.
Media contact Sabrina Spina firstname.lastname@example.org – mobile 338.6674289
Nice Insight, established in 2010, is the research division of That’s Nice, A Science Agency, providing data and analysis from proprietary annual surveys, custom primary qualitative and quantitative research as well as extensive secondary research. Current annual surveys include The Nice Insight Contract Development & Manufacturing (CDMO/CMO), Survey The Nice Insight Contract Research - Preclinical and Clinical (CRO) Survey, The Nice Insight Pharmaceutical Equipment Survey, and The Nice Insight Pharmaceutical Excipients Survey.
Olon Group is a global leader in the development and production of active pharmaceutical ingredients for CDMO and Generics, a reliable and preferential partner to the pharmaceutical, biotech, and specialty ingredients markets. With a 2021’s turnover of 580 Mio$, OLON supplies 300 APIs for the Generic market.
Thanks to all the 2.300 employees, and to highly qualified R&D team – more than 300 people – OLON can offer complete integrated packages and services to support the full development of APIs based on strong knowledge in both Chemical and Biological process, all of them under a full cGMP and regulatory coverage – holder of about 160 active US DMFs and 79 granted CoS. Headquartered in Rodano (Milan, Italy), OLON has 11 manufacturing facilities - 8 located in Italy, 1 in Spain, 1 in USA and 1 in India, designed in compliance with the strictest international requirements, and 3 branch offices in Hamburg (Germany), Florham Park NJ (USA) and Shanghai (China). www.olonspa.com/